Latest net tangible assets for MDGL: $540M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Madrigal Pharmaceuticals (MDGL) currently reports a net tangible assets of $540M as of March 2026. That compares with $710M in the prior-year period — down 23.5% year over year. Use the charts on this page to explore Madrigal Pharmaceuticals's net tangible assets history and peer comparisons.
Madrigal Pharmaceuticals's net tangible assets decreased from $710M to $540M — a 23.5% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Madrigal Pharmaceuticals reported $540M in net tangible assets as of March 2026. That compares with $710M in the prior-year period — down 23.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current net tangible assets of $540M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Madrigal Pharmaceuticals, and consider following MDGL for alerts when major investors trade the stock.
Madrigal Pharmaceuticals is classified in the Healthcare sector. On net tangible assets, it currently shows $540M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MDGL with unrelated industries.